Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
Hideaki Katagiri,1 Masanori Taketsuna,2 Shinpei Kondo,3 Kenta Kajimoto,4 Etsuko Aoi,5 Yuka Tanji1 1Bio-Medicines, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, Japan; 2Statistical Sciences, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, Japan; 3Post Marketing Study Ma...
Guardado en:
Autores principales: | Katagiri H, Taketsuna M, Kondo S, Kajimoto K, Aoi E, Tanji Y |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2e48f8bb99f147df94bc5b0b241a6263 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study
por: Katagiri H, et al.
Publicado: (2018) -
Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia
por: Yang F, et al.
Publicado: (2018) -
Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
por: Anand E, et al.
Publicado: (2016) -
Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
por: Okazaki K, et al.
Publicado: (2017) -
The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
por: Liang Y, et al.
Publicado: (2017)